The Filing Desk

LENZ Therapeutics vs Entrada Therapeutics

LENZ Therapeutics LENZ · Entrada Therapeutics TRDA · Biotechnology

Entrada Therapeutics reported revenue of $25 million in fiscal 2025, 1.3 times LENZ Therapeutics' $19 million in fiscal 2025. LENZ Therapeutics had an operating margin of -477.5%, against -621.1% at Entrada Therapeutics. Free cash flow was −$70 million at LENZ Therapeutics and −$130 million at Entrada Therapeutics.

Side by side

LENZ TherapeuticsEntrada Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$19M$25M
Revenue growth—−87.9%
Revenue growth a year, last 5 years——
Gross margin97.8%—
Operating margin−477.5%−621.1%
Net margin−430.2%−565.5%
Free cash flow−$70M−$130M
Free cash flow margin−366.7%−509.6%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count35.4%6.1%
Last close$3.34$4.64
P/E at the last close——
Insider trades, last 12 monthsbought $365,553, sold $0bought $291,124, sold $6.7 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
LENZ TherapeuticsEntrada Therapeutics
Operating margin
Percent of revenue
LENZ TherapeuticsEntrada Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LENZ TherapeuticsEntrada Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the LENZ Therapeutics and Entrada Therapeutics pages.